Products - Pancreatic cancer | Topic | NICE

Showing 5 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 April 2026
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC